Consolidated figures · ₹ crore
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,356 | 1,470 | 1,186 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 | |
| COGS | — | — | 480 | 463 | 355 | 153 | 272 | 71 | 60 | 74 |
| Gross profit | — | — | 706 | 596 | 507 | 84 | -84 | 78 | 56 | -4 |
| — | — | 494 | 588 | 483 | 92 | 103 | 111 | 69 | 148 | |
| — | — | 212 | 8 | 24 | -8 | -187 | -33 | -13 | -151 | |
| OPM % | — | — | 17.9% | 0.8% | 2.8% | -3.4% | -100.1% | -22.4% | -10.8% | -216.3% |
| Depreciation | — | — | 56 | 67 | 55 | 18 | 108 | 20 | 20 | 26 |
| Interest | — | — | 79 | 59 | 54 | 40 | 36 | 2 | 3 | 4 |
| — | — | 11 | 8 | 10 | 1 | 1 | 10 | 4 | 6 | |
| Profit before tax | 100 | 296 | 88 | -109 | -76 | -65 | -331 | -46 | -31 | -175 |
| Tax | — | — | 10 | -0 | 2 | 3 | -2 | -0 | 0 | 0 |
| Tax % | — | — | 11% | -0.3% | 2.7% | 4.4% | -0.6% | -0.8% | 0.4% | 0.1% |
| 84 | 222 | 78 | -109 | -78 | -68 | -329 | -45 | -32 | -175 | |
| PAT margin % | 6.2% | 15.1% | 6.6% | -10.3% | -9% | -28.5% | -175.6% | -30.5% | -27.1% | -250.6% |
| EPS (₹) | — | — | 18.4 | -13.2 | -18.8 | -8.2 | -39.6 | -5.5 | -3.9 | -21.2 |
| EPS adjusted (₹) | 10.3 | 27.4 | — | -13.2 | -9.4 | -8.2 | -39.6 | -5.5 | -3.8 | -21.2 |
| — | — | 2.2% | — | — | — | — | — | — | — | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 505 | 708 | — | 818 | 415 | 348 | 23 | -22 | -52 | -227 |
| Minority interest | — | — | — | — | 0 | 0 | — | — | — | 0 |
| 665 | 829 | — | 889 | 326 | 359 | 379 | 377 | 847 | 397 | |
| 857 | 513 | — | 486 | 532 | 543 | 570 | 579 | 109 | 567 | |
| Total equity & liabilities | 2,044 | 2,066 | — | 2,210 | 1,289 | 1,266 | 988 | 951 | 921 | 753 |
| 814 | 879 | 965 | 1,045 | 502 | 520 | 278 | 418 | 408 | 386 | |
| CWIP | 94 | 76 | — | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | — | 86 | 199 | 199 | 199 | 169 | 169 | 181 |
| 1,133 | 1,107 | — | 990 | 529 | 507 | 491 | 344 | 328 | 170 | |
| Total assets | 2,044 | 2,066 | — | 2,210 | 1,289 | 1,266 | 988 | 951 | 921 | 753 |
As reported in NSE results XBRL. Segment result is before tax and finance costs.
Latest reported period · 31 Mar 2024 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities |
|---|---|---|---|---|
| Pharma Business | 143.17 | -27.33 | — | 0 |
| Speciality Chemicals Business | 5.9 | -26.03 | — | 0 |
₹ crore by fiscal year
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| 58 | 21 | 80 | 567 | -658 | 14 | -24 | -11 | 8 | |
| -68 | -164 | -196 | 404 | 523 | -1 | 28 | 5 | -1 | |
| 35 | 186 | 72 | -1,015 | -10 | -16 | -6 | 5 | -6 | |
| Net cash flow | 25 | 44 | -44 | -44 | -146 | -3 | -2 | -1 | 1 |
| Free cash flow | — | — | -33 | 567 | -658 | 13 | -24 | -15 | 8 |
| CFO / Operating profit % | — | 10.1% | 981.1% | — | — | — | — | — | — |